Navigation Links
Gerresheimer Discontinues Marginal Operations
Date:6/18/2008

DUSSELDORF, Germany, June 18 /PRNewswire-FirstCall/ --

- Sale of Consumer Healthcare Business

- Concentration on Core Business of Pharmaceutics and Life Science

Gerresheimer AG, the leading manufacturer of glass and plastic products for the pharma & life science industry, is selling its consumer healthcare business. As previously announced, the Dusseldorf company is thereby discontinuing operations which are not part of the core business of pharmaceutics and life science.

"The consumer healthcare business did not fit in with our strategy of focussing on the fields of pharmaceutics and life science. In addition, because of the lack of synergies with the core business, our return requirements for the consumer healthcare business were not fulfilled," says Gerresheimer CEO Dr. Axel Herberg.

The consumer healthcare business, which comprises the production of toothbrushes and other interdental articles and most recently achieved annual sales of EUR24m, was part of the Wilden Group, which was acquired in January 2007. The purchaser is the Krallmann Group. Through the acquisition, Krallmann intends to expand its own plastic processing division and to continue the business under the traditional "Interbros" trademark. The transaction takes place with effect on 1 June 2008. The contractual parties have agreed to keep further details confidential.

Early this year, Gerresheimer already discontinued the marginal business of aluminium packaging with sales of EUR3.3m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharma-ceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press Contact Investor Relations

Burkhard Lingenberg Anke Linnartz

Director Corporate PR & Marketing Director Corporate Investor Relations

Telephone +49-211-6181-250 Telephone +49-211-6181-314

Telefax +49-211-6181-241 Telefax +49-211-6181-121

E-mail E-mail

b.lingenberg@gerresheimer.com a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moodys Raises Rating for Gerresheimer
2. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
3. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
4. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
5. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
6. Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
7. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
8. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
9. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
10. Medimetriks Pharmaceuticals, Inc. Begins Operations
11. Kendle Appoints Patricia Williams Vice President, Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):